Bernstein raised the firm’s price target on Johnson & Johnson to $193 from $172 and keeps a Market Perform rating on the shares. The firm cites improved outlook for Innovative Medicine growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Balanced Outlook on Johnson & Johnson: Strong Performance Amidst Market Challenges Justifies Hold Rating
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Trump Weekly: White House announces drug pricing deal with Pfizer
- Analyst Sees ‘Attractive Entry Point’ for Johnson & Johnson Stock (JNJ) after Trump-Pfizer Deal
- Apple downgraded, Alibaba upgraded: Wall Street’s top analyst calls